Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Autors principals: V. I. Ignatyeva (Autor), S. V. Moiseev (Autor), N. M. Bulanov (Autor), E. A. Karovajkina (Autor), A S. Moiseev (Autor)
• Format: Llibre
• Publicat: IRBIS LLC, 2019-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...